Safety and efficacy of natalizumab in children with MS
Posted: Thu Sep 16, 2010 4:56 am
Abstract
OBJECTIVE: To describe the effect of natalizumab in the treatment of subjects with active multiple sclerosis (MS) treated before the age of 18 years.
METHODS: Nineteen paediatric subjects with MS (mean age 14.6 2.2 years, mean number of attacks 5.2 1.9 during the pretreatment phase of 27.7 19.7 months, median pretreatment Expanded Disability Status Scale score [EDSS] 2.5, range 1.0-5.0) were treated with natalizumab at the dose of 300 mg every 28 days. After treatment initiation, patients were reassessed clinically every month; brain MRI was performed at baseline and every 6 months.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1408